02:24 , Mar 9, 2019 |  BioCentury  |  Politics, Policy & Law

Top-down solution to the U.K. Orkambi debacle

Cystic fibrosis patients hope that a meeting on Monday between Vertex and the U.K. Health Secretary will break the deadlock that has prevented reimbursement of Orkambi by NHS. If it works out, patients in England...
01:00 , Mar 9, 2019 |  BioCentury  |  Finance

Seventure maps its microbiome future

Seventure Partners' second microbiome-based fund aims to foster a generation of companies beyond those focused only on live therapeutics. On March 5, the firm announced a first close of Health for Life Capital II, intended as...
00:51 , Mar 9, 2019 |  BC Extra  |  Clinical News

AMAG sinks after Makena misses confirmatory trial

AMAG lost $2.43 (18%) to $11.29 on Friday after reporting that intramuscular Makena hydroxyprogesterone caproate -- the drug that created a political firestorm over its pricing eight years ago -- missed the co-primary endpoints in...
00:15 , Mar 9, 2019 |  BC Extra  |  Clinical News

Jounce seeking tumor-agnostic approach for ICOS agonist

Jounce said the ICOS hi CD4 T cells biomarker could allow the company to take a tumor-agnostic approach for its ICOS agonist vopratelimab (JTX-2011) to select patient populations more likely to respond to the therapy....
00:09 , Mar 9, 2019 |  BC Extra  |  Company News

Novo opens incubator in China

Novo Nordisk launched an incubator in China to accelerate the discovery and development of new drugs for chronic and metabolic diseases. Novo Nordisk A/S (NYSE:NVO; CSE:NOVO B) hopes INNOVO will make the company's Beijing R&D...
23:03 , Mar 8, 2019 |  BC Extra  |  Company News

Merck partners with King’s College to develop non-opioid pain therapies

Merck has partnered with King's College London to translate research elucidating HCN2 as a pain target to develop non-opioid treatments for chronic neuropathic pain. The deal builds on work from the lab of Peter McNaughton...
22:15 , Mar 8, 2019 |  BC Extra  |  Company News

FDA panel does not back broad reach of Sanofi's dengue vaccine

Sanofi's dengue vaccine did not win the support of an FDA panel for its proposed population of individuals ages 9-45 Thursday, but the panel did back the vaccine's use in adolescents. The vote came as...
20:56 , Mar 8, 2019 |  BioCentury  |  Emerging Company Profile

Synbal: Gene driving on parallel tracks

Synbal is tapping new genetic approaches to develop both rodents with humanized metabolisms and cell therapies for lysosomal storage diseases. Ethan Bier, Valentino Gantz and Tsvi Goldenberg spun out Synbal Inc. from the University of...
20:53 , Mar 8, 2019 |  BC Extra  |  Preclinical News

Janssen, Scripps discover small molecule for flu

Janssen and Scripps have generated an oral compound for treating flu that inhibits the HA protein on influenza H1 and H5 strains. Recent studies have led to the development of broadly neutralizing antibodies (bNAbs) that...
20:08 , Mar 8, 2019 |  BC Week In Review  |  Clinical News

Santhera's Raxone slows loss of respiratory function in real-world DMD study

Santhera said long-term treatment with Raxone idebenone reduced the annual rate of decline in percent predicted forced vital capacity (FVC) by 50% for up to six years in the retrospective real-world SYROS study in patients...